VACCINE TECHNOLOGIES MARKET ANALYSIS

Market News

Recent Developments

New product launches/approval

• In January 2022, GlaxoSmithKline plc, a multinational pharmaceutical and biotechnology company, launched a new vaccine, Shingrix, a non-live, recombinant subunit adjuvant vaccine, given intramuscularly in two doses to help protect against shingles (herpes zoster) in Singapore. It is the first shingles vaccine indicated for use in those who are at increased risk of the disease due to immunodeficiency or immunosuppression caused by known disease or therapy.
• In September 2022, the U.S. President Joe Biden announced the launch of an annual COVID-19 vaccine for all citizens of the country above 12 years of age to protect people from the disease and its variants. The new vaccine will provide protection from the new omicron strain of the COVID-19 virus, which did not exist when the original vaccine was developed.
• In July 13, 2022, the U.S. Food and Drug Administration (FDA) granted an emergency use authorization (EUA) for Novavax COVID-19 Vaccine, indicated for the prevention of COVID-19 caused by SARS-CoV-2 in patients 18 years of age and older. The EUA was issued to Novavax Inc., a U.S.-based biotechnology company. Moreover, on June 18, 2022, the Centers for Disease Control and Prevention (CDC) approved COVID-19 vaccination for young children who are at least 6 months old. i.e. around 20 Bn children in the U.S. under 5 years are newly eligible for vaccination.

Acquisition and partnerships

• In 2022, Pfizer acquired ReViral, a U.K.-based biotech company that is developing a new type of influenza vaccine. The acquisition will give Pfizer access to ReViral's proprietary technology, which uses gene editing to create more effective influenza vaccines.
• In 2022, Moderna, Inc., a biopharmaceutical company, acquired Kymera Therapeutics, a U.S.-based biotech company that is developing new cancer vaccines. The acquisition will give Moderna access to Kymera's proprietary technology, which uses messenger RNA (mRNA) to create personalized cancer vaccines.
• In 2022, GSK, a pharmaceutical company entered into a partnership with CureVac, a Germany-based biotech company, to develop and commercialize mRNA vaccines. The partnership will combine GSK's expertise in vaccine development and manufacturing with CureVac's proprietary mRNA technology.
• On August 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) entered into an agreement with Moderna, Inc., a biotechnology company, to manufacture and deliver 100 Bn doses of COVID-19 vaccines produced by the company in the U.S. by 2021